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Abstract
Approximately 50% of patients with muscle-invasive bladder cancer (MIBC) develop metastatic disease, which is almost
invariably lethal. However, our understanding of pathways that drive aggressive behavior of MIBC is incomplete. Members
of the FOXA subfamily of transcription factors are implicated in normal urogenital development and urologic malignancies.
FOXA proteins are implicated in normal urothelial differentiation, but their role in bladder cancer is unknown. We examined
FOXA expression in commonly used in vitro models of bladder cancer and in human bladder cancer specimens, and used a
novel in vivo tissue recombination system to determine the functional significance of FOXA1 expression in bladder cancer.
Logistic regression analysis showed decreased FOXA1 expression is associated with increasing tumor stage (p,0.001), and
loss of FOXA1 is associated with high histologic grade (p,0.001). Also, we found that bladder urothelium that has
undergone keratinizing squamous metaplasia, a precursor to the development of squamous cell carcinoma (SCC) exhibited
loss of FOXA1 expression. Furthermore, 81% of cases of SCC of the bladder were negative for FOXA1 staining compared to
only 40% of urothelial cell carcinomas. In addition, we showed that a subpopulation of FOXA1 negative urothelial tumor
cells are highly proliferative. Knockdown of FOXA1 in RT4 bladder cancer cells resulted in increased expression of UPK1B,
UPK2, UPK3A, and UPK3B, decreased E-cadherin expression and significantly increased cell proliferation, while
overexpression of FOXA1 in T24 cells increased E-cadherin expression and significantly decreased cell growth and invasion.
In vivo recombination of bladder cancer cells engineered to exhibit reduced FOXA1 expression with embryonic rat bladder
mesenchyme and subsequent renal capsule engraftment resulted in enhanced tumor proliferation. These findings provide
the first evidence linking loss of FOXA1 expression with histological subtypes of MIBC and urothelial cell proliferation, and
suggest an important role for FOXA1 in the malignant phenotype of MIBC.
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Introduction
It is estimated that in 2011 over 69,250 people in the United
States will be diagnosed with carcinoma of the urinary bladder [1].
More than 90% of bladder cancers are histopathologically
classified as urothelial cell carcinomas (UCC), while adenocarci-
nomas, squamous cell carcinomas (SCC) and small cell carcinomas
represent less common histological variants. Most patients present
with non-invasive disease, but often develop recurrence, some-
times with progression to stromal invasion. Thus, vigilant
surveillance of these patients by periodic cystoscopy and urine
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ment for patients with Ta or Tis disease is therefore extraordi-
narily expensive [1]. On the other hand, clinical intervention
following the diagnosis of muscle invasive bladder cancer (MIBC;
tumor stage$T2) typically entails radical cystectomy. Despite
aggressive surgical intervention, approximately 50% of patients
undergoing radical cystectomy will experience disease recurrence,
usually in the form of metastatic disease. The development of
metastatic disease is almost invariably lethal, and it is estimated in
2011 that over 14,990 individuals in the United States will perish
from metastatic bladder cancer in the United States [1].
Relative to other malignancies, bladder cancer is severely
understudied and underfunded. Given the high cost of surveillance
and high mortality rate in patients with advanced disease,
increased efforts to define the biological pathways critical to such
pressing clinical problems of tumor recurrence, as well as
progression to muscle invasion, and/or distant metastasis are
needed. One approach is to identify those pathways that influence
normal differentiation that are perturbed during tumor initiation
and progression. One group of proteins that appears to play an
important role in the development and control of tissue-specific
expression in bladder urothelium consists of select members of the
Forkhead Box (FOX) family of transcription factors. Several recent
reports have implicated a central role for one member of this
family, FOXA1, in urothelial differentiation [2,3,4,5,6,7]. While
FOXA1 is expressed in normal adult murine and human
urothelium, the extent of FOXA family member expression in
bladder carcinoma is unknown. Since other FOX proteins have
been implicated in the development and progression of a variety of
malignancies [8], we initiated a study to interrogate FOXA family
member expression in human bladder cancer cell lines and in
human tumor samples, as well as to determine the functional role
of FOXA1 in a tissue recombination model of urothelial tumor cell
biology.
Materials and Methods
Ethics Statement
De-identified human bladder tissue samples were obtained from
the Vanderbilt Tissue Acquisition Core via the Department of
Pathology in accordance with Vanderbilt IRB protocols. Tissue
microarrays were created as previously described [9] from de-
identified human bladder tissue obtained from the University of
Virginia, and was used in accordance with University of Virginia
IRB protocols. All patients signed informed consent approving the
use of their tissues for unspecified research purposes. All
experiments involving animals were conducted as defined in
Vanderbilt animal protocol number M-10-411, and according to
the Animal Welfare Act and approved by the Vanderbilt
Institutional Animal Care and Use Committee. Animal care/
welfare and veterinary oversight was provided by the Vanderbilt
Divison of Animal Care.
Cell culture
The previously established human bladder cancer cell lines
RT4 [10] and T24 [11] were maintained in McCoy’s modified
medium supplemented with 10% FBS. J82 [12], 5637 [13] and
UMUC-3 [14] human urothelial cancer cell lines were cultured
in DMEM with L-glutamine and high glucose (4.5 g/L;
Mediatech) supplemented with 10% FCS (Atlanta Biologicals)
and 100 units/mL penicillin/streptomycin (BioWhittaker/Cam-
brex). 253J–P and 253J-BV [15] cells were obtained through a
material transfer agreement from the laboratory of Dr. Colin
Dinney (University of Texas MD Anderson Cancer Center) and
cultured in MEM (Mediatech) supplemented with 10% FCS
(Atlanta Biologicals), 100 units/mL penicillin/streptomycin (Bio-
Whittaker/Cambrex), 10 mmol/L sodium pyruvate (Mediatech),
1x nonessential amino acids (Mediatech) and 2x MEM vitamin
solution (Mediatech). SCaBER cells [16] were obtained from
ATCC and maintained in Minimum essential medium (Eagle)
(Invitrogen) containing 10% FCS with 2 mM L-glutamine
(Mediatech) and Earle’s balanced salt solution (Invitrogen)
adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-
essential amino acids, and 1.0 mM sodium pyruvate. The
previously established human prostatic adenocarcinoma cell lines
LNCaP [17] and PC3 [18] and the hepatocellular carcinoma cell
line HepG2 [19] were maintained in RPMI 1640 supplemented
with 10% FBS. All cell lines were maintained at 37uCi n5 %
CO2.
PCR
RNA extraction was performed with RNeasy kits (Qiagen)
according to manufacturer’s protocol with Dnase digestion.
Subsequently, cDNA was amplified according to standard
protocols. PCR was performed with primer sets for human
FOXA1 (fwd-CGCTTCGCACAGGGCTGGAT, rev-
TGCTGACCGGGACGGAGGAG), FOXA2 (fwd-TGCCATG-
CACTCGGCTTCCA, rev-CCCAGGCCGGCGTTCATGTT),
FOXA3 (fwd-CTGGCCGAGTGGAGCTACTA, rev-GAG-
GATTCAGGGTCATGTAGGA). Primer sequences used for
standard PCR of uroplakin transcripts have been previously
reported [20]. Primer sets for Q-RT-PCR analysis include
UPK1A fwd-GGTGTGGGTGCCGCACTCTG, rev-GGTC-
GGTGTCCGCGCTGTAG), UPK1B (fwd-GCCCTACCG-
TGTGCGCAGAAA, rev-AGCAGGCCCTGGAAGCAACG),
UPK2 (fwd- CTCTGCTGTCCCCAGGGGCT, rev-GGCAAC-
CAGCAGGCTCTCCG), UPK3A (fwd-TCACTGGCACC-
CACGAGGTCT, rev-CGTTGAGCCCAGTGGGGTGTT),
and UPK3B (fwd- CCCTGGCCCTGGACCCTATCG, rev-
CCACAGGCTGGAGAAGCGCA). GAPDH (fwd-TGCAC-
CACCAACTGCTTAGC, rev-GGCATGGACTGTGGTCAT-
GAG) was used as reported previously [21] as an internal control
for PCR reactions.
Human tissue samples
The present study included two separate patient cohorts from
Vanderbilt University Medical Center and the University of
Virginia Medical Center (summarized in Table 1). All studies were
performed following approval of the Internal Review Boards at
each of the participating institutions. Whole tissue sections were
prepared from transurethral endoscopic tumor resection samples
from 18 patients with low grade stage Ta disease treated at
Vanderbilt University Medical Center. Tissue samples from
primary tumor samples derived from the University of Virginia
patient cohort were represented on a previously described tissue
microarray (TMA) [9]. Quadruplicate tissue cores (0.6 mm) of
viable tumor were harvested from archived zinc-formalin-fixed
tissue blocks of 167 cystectomy specimens. The original pathology
slides were reviewed to record the histologic subtype and grade as
well as confirm the pathologic stage of the tumors. Tumors were
histologically graded on a scale from 1–4, with grade 4 as the
highest grade. Of 19 patients who received neoadjuvant therapy, 6
were treated with radiation therapy, 8 with chemotherapy and the
remainder with combination chemoradiotherapy. The TMA
cohort included 112 urothelial carcinomas, 21 squamous cell
carcinomas, 5 primary bladder adenocarcinomas, 3 small cell
(high-grade neuroendocrine) carcinomas, 1 mixed urothelial and
squamous carcinoma, 1 adenocarcinoma with sarcomatoid foci
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additional TMA from the University of Virginia consisted of
quadruplicate tissue cores (0.6 mm) of lymph node metastases
dissected from 28 patients represented in the primary tumor TMA
(Table 1).
In addition to the tumor samples for which demographic data
were available as described in Table 1, archival tissue consisting of
tumor and normal adjacent tissue (NAT) from 10 patients who
underwent cystectomy for advanced bladder cancer at Vanderbilt
University were collected for the analysis of FOXA1 and
uroplakin. In addition, archival tissue consisting of 21 patients
with non-keratinizing squamous metaplasia were identified. Of
these, 2 patients had areas of keratinizing squamous metaplasia,
and 15 patients had NAT, which served as a control.
Immunohistochemistry and dual immunofluorescence
Immunohistochemistry was performed as previously described
[22,23]. Briefly, slides were deparaffinized, rehydrated through a
series of graded alcohols and washed in double deionized water for
5 minutes. Tissues were then placed in antigen unmasking solution
(Vector Labs, Burlingame, CA) and antigen retrieval was
performed by microwaving samples for 20 minutes at 30% power
in a 900 watt microwave oven. Slides were then cooled to room
temperature, and then washed 3 times for 10 minutes in PBS
(pH 7.4). For immunohistochemistry, all incubations were per-
formed at room temperature unless otherwise stated. Endogenous
peroxidase activity was blocked with the use of Peroxidase
blocking reagent (Dako North America, Carpinteria, CA) for
20 minutes, after which sections were again washed in PBS 3 times
for 10 minutes. Prepared slides were incubated in goat serum for
30 min to reduce non-specific antibody binding. Slides where then
incubated overnight at 4uC in a humidified chamber with 1:1000
dilutions of either goat polyclonal FOXA1 (Santa Cruz Biotech-
nology, Santa Cruz CA), goat polyclonal FOXA2 (Santa Cruz
Biotechnology) or a pan-uroplakin antibody, AUM [24] diluted
1:5000 in PBS. Slides were then washed 3 times for 10 min with
PBS and biotinylated secondary antibody diluted in PBS was then
added. Primary antibody was visualized using the Vectastain Elite
ABC Peroxidase kit (Vector Labs) according to the manufacturer’s
protocol with DAB in substrate buffer as chromogen (Thermo
Scientific, Fremont CA). For FOXA1 and FOXA2, slides were
scored for the presence or absence of specific nuclear staining. The
positive control for FOXA1 were wild-type murine prostate tissue,
and the positive control for FOXA2 was prostatic tissue from
previously described Probasin-T-antigen//Dominant active beta-
catenin bigenic mice [21]. For pan-UPK, the presence or absence
of cytoplasmic immuno-reactivity in tumor cells was recorded.
Immunostaining of human bladder tissue was performed for the
squamous epithelium marker cytokeratin 10 (1:100; Dako,
Carpinteria CA), and the basal cell marker cytokeratin 14
(1:200; Dako). Immunofluorescence staining was performed on
human bladder tissues with antibodies for Ki67 (1:100; Dako;
Carpinteria, CA; clone MIB-1) and FOXA1 (1:100: Santa Cruz).
Stable Cell Line Generation
Following transfection of Phoneix packaging cells, retroviral
particles were filtered and purified, and viral particles were used
for infection of RT4 and T24 target bladder cell lines. Following
retroviral infection, RT4 cells were puromycin selected to stably
express a FOXA1 targeted shRNA construct resulting in
decreased FOXA1 expression (RT4-FOXA1 KD) or scrambled
shRNA expressing control cells (RT4-Scr) according to manufac-
tures instructions (Origene, Rockville, MD). Similarly, T24 cells
were puromycin selected following viral infection to stably express
pLPCX plasmid containing a FOXA1 insert (T24-FOXA1) or
empty vector (T24-pLPCX). Data from microarray analysis
described in this manuscript will be deposited in a publically
available database in compliance with MIAME guidelines.
Table 1. Tissue sources and demographic information.
Vanderbilt University Cohort
Gender (%) Male 14 (77%)
Female 4 (23%)
Mean age 67
T stage (%) Ta 18 (100%)
N stage N/A
Grade Low
University of Virginia Cohort
Gender (%) Male 103 (71%)
Female 42 (29%)
Mean age 67
T stage (%) Ta
T1
T2
T3
T4
4 (3%)
6 (4%)
47 (32%)
64 (45%)
23 (16%)
N stage (%) N0
N1 or higher
39 (60%)
26 (40%)
Grade (%) Grade 1–2
Grade 3
Grade 4
26 (23%)
72 (63%)
17 (14%)
doi:10.1371/journal.pone.0036669.t001
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All animal experiments were performed in accordance with
institutional IACUC approval. Isolation of embryonic bladder
mesenchyme (eBLM), preparation of tissue recombinants, and
kidney capsule surgeries were performed as described previously
[2]. Pregnant rats (Harlan Laboratories, Tampa FL) were
sacrificed at embryonic day 16 (E16) (plug day=0). Bladders
were then microdissected from isolated embryos, and embryonic
bladders were separated from the urogenital sinus at the bladder
neck and the attached ureters carefully dissected. Whole bladders
were then placed into calcium and magnesium-free Hanks’ saline
(Gibco) containing 25 mM EDTA (Sigma, St. Louis MO) for
90 min to release the bladder urothelium. The mesenchyme and
urothelium were separated manually under microscopic exami-
nation, leaving the mesenchyme behind as a bladder shell. Fifty
thousand RT4-Scr cells and RT4-FOXA1 KD cells were re-
suspended in 50 microliters of a 3:1 ratio of rat tail collagen and
setting solution, and were plated in 10 cm dishes. Following the
insertion of 1 eBLM per aliquot, tissue recombinants were placed
at 37uC to promote solidification. McCoy’s modified medium
(Gibco) containing 10% FBS was then applied to solidified grafts
and incubated overnight. The following day, two tissue recombi-
nants were placed under the kidney capsule of the left kidney of 5
SCID mice, resulting in a total of 10 grafts. Three weeks following
implantation, mice were injected with BRDU and sacrificed.
Dissected kidneys containing tissue recombinants were fixed in
formalin and subjected to standard processing in preparation for
immunohistochemistry. Animal experiments were repeated once.
Tumor volume measurements were performed by standard
methods and are represented as fold tumor volume.
Western blotting analysis
Western blotting analysis was performed as reported previously
[25]. Briefly, cell lysates were prepared with Complete Lysis-M kit
(Roche, Nutley NJ) as per manufacture protocol and protein
concentrations were determined via standard BCA protocol
(Pierce, Rockford, IL). Cell lysates (30 mg) were subjected to
electrophoresis on a 10% Bis–Tris gels for 50 min at 200 V.
Electrophoretic transfer to nylon reinforced nitrocellulose mem-
branes (Osmonics, Minnetonka, MN) was performed overnight at
30 V, followed by Ponceau-S staining (Sigma) in order to verify
equal protein loading and transfer. Membranes were blocked
overnight in in 5% non-fat dry milk (NFDM), 0.1% Tween 20
(Sigma) in 1x Tris buffered saline. The following day, nitrocellu-
lose membranes were incubated with goat anti-FOXA1 (Santa
Cruz; 1/1000), anti E-cadherin (BD Biosciences; 1/1000) or anti
beta actin (Sigma; 1/1000) followed by appropriate HRP-
conjugated secondary antibody (Jackson Labs, Bar Harbor, ME)
at a dilution of 1/2,000.
Crystal violet growth assays
Cells (5,000 per well) were plated in 24 well culture dishes
(Falcon) and allowed to attach overnight in McCoy’s medium
containing 10% FBS and 0.5 mg/ml puromycin. The following
day, culture medium was aspirated, and cells were fixed in 11%
glutaraldehyde (Sigma) and incubated at room temperature on an
orbital shaker set at 500 cycles/min. Cells were then washed 3
times by submerging in deionized water and allowed to air dry and
stained with 0.1% crystal violet dissolved in 200 mM boric acid
(Sigma), pH 8.0. Following incubation for 20 minutes on an
orbital shaker, excess crystal violet was then removed by washing
in deionized water and allowed to air dry. Crystal violet stain was
subsequently dissolved in 10% acetic acid (Sigma) and absorbance
was read at 590 nm following background subtraction. Crystal
violet growth assays were performed for five days in triplicate and
repeated twice.
In vitro invasion assays
In vitro invasion assays were performed as previously reported
[26]. Falcon cell culture inserts (8 mm pores) were washed twice
with McCoy’s medium and subsequently coated with 20 mlo f
reduced growth factor Matrigel (BD Biosciences, Franklin Lakes
NJ) diluted 1:6 and allowed to solidify for 30 minutes. RT4-Scr,
RT4-FOXA1 KD, T24-pLPCX, and T24-FOXA1 (1610
5/well)
were added to individual wells in 200 ml if McCoy’s medium
(10%FBS, 0.5 mg/ml puromycin), and 300 ul of identical medium
was added to the bottom chamber. After 24 and 48 hours
incubation, medium was aspirated from the lower chamber, and
invaded cells were fixed in 5% glutaraldehyde dissolved in 1x PBS
for 10 min at room temperature, and cells were subsequently
washed in deionized water three times. Invaded cells were stained
by adding 0.5% toluidine blue (Sigma) in 2% sodium carbonate
and incubating 20 min, after which toluidine dye and medium was
aspirated from the upper and lower chamber, respectively. The
bottom chamber was then washed three times with deionized
water, and non-invaded cells were removed by wiping the inside of
the upper chamber gently with a cotton swab, and invaded cells
were counted under a 20x objective. Invasion assays were
performed in triplicate and repeated twice.
Statistical analysis
Associations between nuclear FOXA1 and FOXA2 staining and
clinicopathologic parameters were assessed using standard univar-
iate methods. FOXA1 and FOXA2 expression status was
summarized by tumor stage, nodal status, histologic type and
grade. x2 tests of association were performed between dichoto-
mized expression values and each pathologic parameter. For
FOXA1 expression, logistic regression was used to test the
predictor ‘‘tumor stage’’ as an ordinal variable with five categories
(Ta, T1, T2, T3 and T4). Tests of association were performed
both on the entire data set and the subset of TCC samples only.
Statistical analysis was performed in SAS 9.2. All tests were
assessed at a=0.05. Statistical evaluation of differences in tumor
volume between RT4-Scrambled and RT4-FOXA1 KD were
performed by standard univariate methods, with p,0.05 consid-
ered significant.
Results
FOXA1 and FOXA2 expression is restricted to specific bladder
cancer cell lines:
In studies of urinary bladder development, nuclear FOXA1
expression was found to be restricted to the urothelial compart-
ment and was maintained in adult urothelium [27]. In contrast, in
situ hybridization analyses indicated expression of FOXA2 during
early embryonic development [28], while no expression was
evident in later stages of urothelial development or in the
urothelium of adult bladders [27]. As an initial step in
characterizing the expression of FOXA family members in
bladder cancer, we performed RT-PCR on the commonly used
human bladder cancer cell lines RT4, T24, J82, 5637, 253J, 253J-
BV, UMUC3 and SCaBER. Interestingly, only the RT4 cell line,
which was originally propagated from a well differentiated tumor
[10], exhibited high FOXA1 expression. In addition, expression of
FOXA1 was associated with the presence of UPK transcripts
(Fig 1A), of which UPK2 is used as a urothelial differentiation
marker. 5637 cells also co-expressed low levels of FOXA1 and
UPK mRNA. T24 cells expressed very low levels of FOXA1 and
FOXA and Bladder Cancer
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Quantitative RT-PCR analysis of SCaBER cells established from
a primary SCC tumor showed that FOXA1 expression was
significantly lower in these when compared to RT4 (Fig. 1B). None
of the cell lines examined expressed FOXA3, a third related
member of the FOXA family (data not shown). As FOXA1
expression was associated with UPK in RT4 and 5637 cells, we
investigated the expression of these markers in human bladder
cancer specimens. Out of 10 samples with FOXA1 positive NAT,
and FOXA1 negative associated tumor, 4 tumors exhibited
negative AUM staining, while 6 tumors retained AUM staining
(Fig. 1C). Taken together, these results indicate that loss of
FOXA1 expression is associated with decreased or absent UPK
expression in widely used human bladder cancer cell lines and in a
subset of human bladder tumor tissue.
FOXA1 knockdown in RT4 cells increases uroplakin
expression
The uroplakin (UPK) family of genes in humans consists of
UPK1A, UPK1B, UPK2, UPK3A and UPK3B [29]. Although
decreased FOXA1 expression appeared to be correlated with
diminished UPK expression in commonly used bladder cancer cell
lines, and in a minority of human cystectomy samples (Fig 1), the
AUM antibody used for these studies recognizes all members of
the uroplakin family [30]. Furthermore, it was previously reported
that knockdown of FOXA1 resulted in both decreases and
increases in the expression of UPK family members [5].
Therefore, it was unclear if altered FOXA1 expression resulted
in changes of individual uroplakin family members. As RT4 cells
express FOXA1 and each member of the UPK family (Fig 1), we
used an shRNA approach to engineer stable RT4 cells with
decreased FOXA1 expression to determine the impact of FOXA1
silencing on UPK expression (Fig 2). Interestingly, microarray
studies performed on RT4-Scr and RT4-FOXA1 KD indicated
FOXA1 KD was associated with increased UPK family member
expression. Quantitative RT-PCR studies of RT4-Scr and RT4-
FOXA1 KD cells validated this observation, showing that FOXA1
KD resulted in significant increases in the expression of UPK1B,
UPK2, UPK3A, and UPK3B (Fig 2C–F). Thus, although FOXA1
and UPK are lost in the majority of cell lines established from high
grade, MI tumors and in a subset of human cystectomy samples,
FOXA1 KD in RT4 cells results in significantly increased UPK
family member expression in vitro.
Loss of FOXA1 expression is associated with advanced
tumor stage and high histologic grade
To determine the extent of FOXA1 and FOXA2 expression in
various stages of bladder cancer, we performed immunohisto-
chemical analysis on human tumor samples (Fig. 3). The
prevalence of FOXA1 expression decreased with increasing tumor
stage (Table 2). FOXA1 was uniformly expressed in stage Ta
bladder tumors, compared to only 67% of stage T1 tumors, 59%
of stage T2 cancers, 42% of stage T3 tumors, and 34% stage T4
neoplasms. Logistic regression analysis demonstrated that loss of
FOXA1 expression was significantly associated with increasing
tumor stage (p,0.001). Loss of FOXA1 expression also occurred
in tumors of higher histologic grade (p,0.001; Table 2). FOXA1
was also negative more often in tumors from female patients.
However, this association failed to reach statistical significance
following normalization to tumor stage and grade (p=0.096).
FOXA2 was not detected in Ta stage tumors and was present only
in 12% of higher stage cancers. There were no significant
associations between FOXA2 expression and tumor stage or
histologic grade.
FOXA1 expression is significantly reduced in keratinizing
squamous metaplasia and squamous cell carcinomas of
the urinary bladder
The majority of bladder cancers are histologically identified as
UCC. SCC is the next most common histological variant of
bladder cancer. A recognized precursor of SCC is the develop-
ment of keratinizing squamous metaplasia (KSM). KSM is distinct
from non-KSM, which is relatively common and benign. As the
prognosis of patients with nonbilharzial SCC of the urinary
bladder is especially grave [31], we compared FOXA1 expression
in KSM, non-KSM and SCC. Histological analysis revealed that
while FOXA1 was expressed in non-KSM (Fig. 4A, inset, left
panel), and overlapped with expression of CK14 positive basal
cells, FOXA1 was not expressed in KSM (Fig. 4A) or most of SCC
(Fig. 4B). FOXA1 expression was lost in 81% of SCC samples
(Fig. 4B) compared to 40% of UCC of the bladder (Fisher’s exact
test, p,0.001) (Table 3). While the majority of SCC is diagnosed
at a relatively advanced tumor stage, the association between SCC
and FOXA1 loss remained significant (p=0.0043) even after
adjusting for tumor stage. Furthermore, FOXA1 staining of a
TMA consisting of metastatic tumor deposits from positive lymph
nodes dissected from 28 patients represented in the primary tumor
TMA (Fig. 4C) revealed a further association between FOXA1 loss
and SCC. Out of the original 28 cases, sufficient tissue for analysis
remained in only 22 samples. Five cases of lymph node metastases
(23%) were negative for FOXA1 expression. Three out of 5
FOXA1-negative lymph nodes (60%) were dissected from patients
diagnosed with primary SCC. Of these, 2 (one stage T4 and one
stage T2) were matched to FOXA1-negative primary tumors, one
was matched to a stage T3 primary tumor with loss of FOXA1
expression. The remaining 2 FOXA1-negative lymph node
metastases were dissected from patients diagnosed with stage T3
TCC and small cell carcinoma, both of which were negative for
FOXA1 expression.
FOXA1-negative urothelium is proliferative and FOXA1
knock-down results in increased tumor proliferation and
decreases in E-cadherin expression
In order to determine the proliferative potential of intra-tumoral
FOXA1 negative urothelium, we performed dual-immunofluores-
cence using antibodies for FOXA1 and the proliferation marker
Ki67 (Figure 5). Interestingly, we found that the presence of
positive FOXA1 staining and Ki67 was relatively exclusive. We
compared RT4-FOXA1 KD cells to control RT4-Scr cells to
determine the impact of altered FOXA1 expression levels on
bladder cell in vitro growth. Additionally, we established T24 cells
stably over expressing FOXA1 to determine the impact of
restoring FOXA1 expression on cell behavior (Fig. 6). Microarray
analysis utilizing Affymetrix Gene Titan chips was subsequently
performed to identify FOXA1 target genes potentially responsible
for any altered behavior of RT4 and T24 cells. Loss of E-cadherin
expression is implicated in bladder cancer progression, and
decreased FOXA activation of E-cadherin expression is implicated
in pancreatic tumor progression [32]. Microarray analysis
indicated overexpression of FOXA1 in T24 cells resulted in
increased E-cadherin expression. Importantly, western blotting
analysis of both RT4 and T24 based cell lines verified the
correlation between altered FOXA1 and E-cadherin expression
(Fig. 6A). We next performed crystal violet growth assays to
identify a potential role for FOXA1 expression in the regulation of
FOXA and Bladder Cancer
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significant increases in cell number at day 4 (Fig. 6B). While there
was a trend towards increased RT4-FOXA1 KD cell growth at
day 5, the difference was not statistically significant (Fig. 6B).
Overexpression of FOXA1 in T24 cells significantly decreased
T24 cell proliferation at days 3, 4, and 5. These results indicate
that alterations in FOXA1 expression influence bladder cancer cell
proliferation. As loss of FOXA1 expression was associated with
increased tumor stage, we additionally performed in vitro invasion
assays to determine the impact of altered FOXA1 expression in
Figure 1. Analysis of FOXA1 and uroplakin expression in vitro and in human bladder tissue. A: A panel of commonly used urothelial cell
lines was screened via traditional RT-PCR for the presence of FOXA1, FOXA2, and FOXA3 transcripts, as well as members of the uroplakin (UPK) family.
HepG2 cells, which express each member of the FOXA subfamily, were used as positive controls (data not shown). RT4 cells exhibited robust
expression of FOXA1 and as previously reported, UPK family members [20]. FOXA2 expression was detected in T24 cells, but was not correlated with
UPK family member expression. FOXA3 was not detected in any tested cell line (data not shown). B:Q-RT-PCR analysis shows FOXA1 expression in the
SCaBER cell line derived from a primary SCC and in T24 is significantly lower compared to RT4. C:Decreased FOXA1 expression is associated with
decreased UPK expression in human tissue. Archival normal adjacent tissue (top panel) and muscle invasive bladder tumor was immunostained with
a pan-UPK antibody, AUM [24] as well as an antibody directed against FOXA1. Out of 10 samples with FOXA1 positive NAT, and FOXA1 negative
associated tumor, 4 tumors exhibited negative AUM staining.
doi:10.1371/journal.pone.0036669.g001
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minimally invasive after 24 hours of incubation (Fig. 6D), and
failed to exhibit significant invasion even after 48 hours (data not
shown). Furthermore, FOXA1 knockdown failed to increase RT4
in vitro cell invasion following 24 and 48 hours of incubation. In
contrast, overexpression of FOXA1 in T24 cells significantly
decreased cell invasion at 24 hours (Fig. 6D). Taken together,
these in vitro studies suggest alterations in FOXA1 expression have
important implications for the growth and invasion of bladder cell
lines. In an effort to determine the impact of reduced FOXA1
expression on RT4 tumorigenicity, we performed tissue recombi-
nation xenografting experiments with RT4-FOXA1 KD cells
(Figure 6E, F, and G). RT4-FOXA1 KD and RT4-Scr cells were
recombined with embryonic bladder mesenchyme (eBLM) and
grafted under the kidney capsule of immune compromised mice as
described in materials and methods. In agreement with in vitro
findings, FOXA1 knockdown resulted in significantly increased in
vivo tumor volume (Figs. 6E and F). Histologically, both control
and FOXA1 knockdown RT4 recombinants resulted in the
formation of relatively well-differentiated tumors complete with
papillary structures and associated fibromuscular stroma (see
H&E, Fig. 6G). In agreement with in vitro invasion assays, FOXA1
knockdown did not promote invasion of RT4 cells. However, the
BrdU labeling index was increased in FOXA1 knockdown
recombinants compared to control (Fig. 6G, bottom panel).
Discussion
Despite clinical intervention, Surveillance, Epidemiology and
End Results (SEER) data collected between 1998 and 2001
indicates the five-year survival rate for patients treated for stage T2
bladder cancer is approximately 63%, while the five-year survival
rate for patients with stage T3 and T4 is 46% and 15%,
respectively. Therefore, a high priority for bladder cancer research
is to identify the genes that contribute to the biological processes
underlying tumor progression and metastasis. In this study, we
provide the first evidence linking alterations in FOXA1 expression
to advanced tumor stage and high histologic grade. In addition, we
report the loss of FOXA1 expression in KSM and in SCC of the
urinary bladder, and show that reduced FOXA1 expression
promotes RT4 xenograft proliferation.
Clinical and transgenic mouse studies have repeatedly impli-
cated two independent molecular pathways instrumental in the
development of urothelial neoplasia [33]. Low grade, Ta stage
non-invasive bladder tumors are associated with activating
mutations in components of the FGFR3 receptor tyrosine kinase
Figure 2. Silencing of FOXA1 in RT4 cells results in increased expression of UPK family members. A: Stable knockdown of FOXA1 in
human RT4 bladder cancer cells (See Figure 6 for FOXA1 protein levels following knockdown in RT4). B: No significant changes in UPK1A were
detected following FOXA1 KD. (C-F): mRNA levels of UPK1B, UPK2, UPK3A, and UPK3B were significantly increased following FOXA1 knockdown.
doi:10.1371/journal.pone.0036669.g002
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often progress to MIBC. Conversely, the initiating lesion for the
development of MIBC is chiefly carcinoma in situ (CIS). While Ta
tumors and urothelial CIS are both associated with loss of
heterozygosity (LOH) of chromosome 9 p and 9 q, progression to
MIBC occurs with inactivating mutations in p53 and the Rb
family of cell cycle repressors, as well as LOH on chromosomes
8 p, 11 p, 13 q, and 14 q [33,34]. The gene for FOXA1 is located
on chromosome 14 q, and we found that FOXA1 expression was
uniformly present in Ta stage tumors, but was lost in Stage T2 or
higher bladder cancers. One potential source of bias is that the
majority (18 out of 22) of Ta stage tumors were acquired from
Vanderbilt. While it will be important for other research groups to
validate our finding that FOXA1 expression is uniformly positive
in Ta stage tumors, it is important to point out that the significant
association between loss of FOXA1 and increasing tumor grade
(p,0.001) and stage (Ta, T1, T2 vs. T3, T4) remains for both
UCC (p=0.009) and SCC (p=0.002) when the University of
Virginia cohort is analyzed alone. Therefore, our results place
FOXA1 loss in a molecular context that is associated with MIBC.
Perhaps initial molecular ‘‘hits’’ resulting in the inactivation of one
allele of FOXA1 occur in urothelial dysplasia/CIS, with
subsequent loss of both alleles or down-regulation of the second
allele occurring in more advanced MIBC. It is important to note
that logistic regression analysis of all histologic tumor types and the
separate subset of UCC tumors alone revealed a significant
association between loss of FOXA1 and increasing tumor stage.
This indicates that although approximately 80% of T2–T4 SCCs
are negative for FOXA1, SCC are not the only cancers that show
FOXA1 loss and advanced tumor stage. These results would seem
to implicate FOXA1 in the neoplastic progression of bladder
cancer, consistent with its potential role in the maintenance of a
differentiated urothelial phenotype. The loss of FOXA1 expression
in most SCCs also suggests that this protein is a key regulator of
the normal urothelial cell phenotype. Our finding that FOXA1
expression was lost only in a minority of lymph node metastases
was surprising, as we expected the majority of lymph node
metastases to exhibit negative FOXA1 staining. It has been
recently reported that cytokeratin 20 positive cells can be detected
in the bone marrow aspirates of cystectomy patients, regardless of
primary tumor stage [35]. This observation and similar ones in the
field of breast and prostate cancer may be explained by the theory
of parallel progression of metastasis [36]. This theory suggests that
the metastatic cascade of tumor cell dissemination to distal tissues
occurs much earlier than commonly thought. The fact that a
minority of lymph node metastases were negative for FOXA1 may
indicate that cancer dissemination to lymph nodes occurs prior to
loss of FOXA1 within the primary tumor. Alternatively, FOXA1
loss may not be important for lymph node metastases, or
microenviornmental cues within the lymph node may somehow
result in reactivation of FOXA1 expression. Still, our analysis
shows approximately one quarter of lymph node metastases are
negative for FOXA1. Most importantly, 3 out of 5 FOXA1-
negative lymph nodes (60%) were dissected from patients
diagnosed with primary SCC, suggesting a particular link between
FOXA1 loss and lymph node metastases in patients with SCC.
Figure 3. FOXA1 expression is lost in most in high grade,
advanced stage muscle-invasive bladder cancers. AJCC stage Ta,
T1, T2, T3 and T4 bladder tumors were immunostained for FOXA1 and
FOXA2. Representative cases are illustrated in top panels. Tis area is
depicted in a patient diagnosed with AJCC T1 stage bladder tumor.
Association between loss of FOXA1 expression and increasing stage
was confirmed by logistic regression (bottom panel, p,0.001). A small
subset of invasive tumors exhibited nuclear expression of FOXA2.
doi:10.1371/journal.pone.0036669.g003
Table 2. Association of FOXA1 Staining with gender, tumor
stage, grade, and nodal status.
Total
FOXA1+
(%)
FOXA12
(%) P value
Gender Male
Female
103
42
56 (54%)
15 (36%)
47 (45%)
27 (64%)
p=0.096
Tumor
Stage
Ta, T1
T2-T4
29
166
27 (93%)
77 (46%)
2 (7%)
89 (54%)*
p,0.001*
Tumor
Grade
G1-2
G3
G4
26
72
17
20 (77%)
39 (54%)
2 (11%)
6 (23%)
33 (46%)
15 (88%)*
p,0.001*
Nodal
Status
N0
N1 or greater
39
26
19 (49%)
13 (50%)
20 (51%)
13 (50%)
p.0.05
doi:10.1371/journal.pone.0036669.t002
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metastases are unknown, and it is possible that FOXA1 status in
metastatic tissue correlates with clinical outcome. Therefore,
future work will be directed toward evaluating this important issue.
After adjusting for tumor stage, our results show a trend towards
a significant association between loss of FOXA1 expression and
female sex (p=0.096). Should future studies reveal a significant
relationship between FOXA1 loss and gender, the fact that
FOXA1 has been described as a ‘‘master’’ of steroid receptor
function in malignancy (reviewed in [37]) indicates further studies
of the relationship between FOXA1 expression and gender in
bladder cancer are warranted. Our laboratory reported the direct
interaction of FOXA1 with the androgen receptor (AR) and
showed the importance of FOXA1 during normal prostate
development [23,38] which is a androgen-regulated process.
Subsequently, it was reported that FOXA1 expression was
essential for estrogen receptor (ER) function and mammary gland
development [39,40]. While incidence of bladder canc-er is
highest among men, tumor recurrence and disease-specific
mortality is higher among women [41,42]. It will be important
to correlate FOXA1 expression with disease specific outcome in
future studies, and to determine the functional significance of
FOXA1 expression for AR and ER activity, as these receptors
have been implicated in the molecular pathogenesis of bladder
tumors.
While this is the first study of FOXA1 expression in bladder
cancer, there is extensive evidence supporting its role in urothelial
differentiation. We previously demonstrated that recombination of
murine embryonic stem cells (ESCs) with murine bladder
mesenchyme induces ESC differentiation into tissue histologically
similar to bladder mucosa. In this model, UPK expression (a
marker of urothelial differentiation) is associated with loss of
FOXA2 expression and maintenance of FOXA1 expression [2,3].
Recently it was shown that treatment of mouse ESCs on a collagen
matrix with all-trans-retinoic acid resulted in the downregulation
of the pluripotency marker Pou5f1 (Oct3/4) and parallel
upregulation of markers of superficial or ‘‘umbrella’’ cells,
including several Upk family members (Upk1a, Upk1b, Upk2,
Upk3a and Upk3b) and Keratin 20 [4]. Induction of these markers
of terminal urothelial differentiation was accompanied by
increased expression of Foxa1 and Foxa2, potentially through
the direct regulation of retinoic acid receptors. Also, It has been
reported that treatment of normal human urothelial (NHU) cell
cultures with the PPAR-c agonist troglitazone and inhibition of
Figure 4. FOXA1 expression is absent in keratinizing squamous metaplasia and squamous cell carcinoma (SCC) of the urinary
bladder. (A) H&E and immunostaining of non-keratinizing (left panel) and keratinizing (right panel) squamous metaplasia for FOXA1, the squamous
cell marker cytokeratin 10, and the basal cell marker keratin 14. Inset on left panel shows positive FOXA1 staining at high magnification. (B) H&E (left
panel) of FOXA1-positive (top) and FOXA1-negative (bottom) samples of human SCC of the urinary bladder are depicted. Most cases (81%) of bladder
SCC showed loss of FOXA1 expression. (C) FOXA1 expression is lost in lymph node metastases of some patients with SCC: H&E (left panel) of FOXA1-
positive UCC (top) and FOXA1-negative SCC (middle and bottom) metastatic lymph node samples isolated from bladder cancer patients are depicted.
doi:10.1371/journal.pone.0036669.g004
Table 3. Histological subtype and FOXA1 status.
Total FOXA1+ (%) FOXA12 (%) p value
SCC 21 4 (19%) 17 (81%)* *p=0.043
TCC 130 78 (60%) 52 (40%)
doi:10.1371/journal.pone.0036669.t003
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subsequent binding of FOXA1 to UPK promoters that results in
increased transcription [5]. However, our immunostaining analysis
showed that out of 10 FOXA1 negative tumors with FOXA1
positive NAT, 6 retained AUM staining, indicating the retention
of UPK family member expression. This is consistent with the
observation that up to 80% of primary tumors retain the
expression of at least one UPK gene [20]. Thus, while a subset
of FOXA1 negative tumors lose UPK expression, loss of FOXA1
and UPK staining are not mutually inclusive. This conclusion is
supported by our finding that stable knockdown of FOXA1
resulted in significant increases in the expression of UPK1B,
UPK2, UPK3A, and UPK3B (Fig. 2). Our finding that reduced
FOXA1 expression results in increased UPK family member
expression is in agreement with those of Varley et. al. [5], which
showed FOXA1 silencing in NHU cells resulted in decreases in
UPK1A, UPK2, and UPK3A, and increases in the expression of
UPK1B and UPK3B.
While the UPK family of genes is expressed in the epithelium of
a relatively limited number of tissues, the mechanisms responsible
for the tissue-specific nature of UPK expression are largely
unknown. The combinatorial control theory of gene expression
[43] suggests the combination of different transcription factors
(and other genetic and epigenetic events), which are themselves
expressed in a temporally and spatially regulated manner,
contributes to the expression of genes in a tissue-specific manner.
While no one transcription factor can be responsible for the
regulation of a given promoter, our results, and those of other
investigators show that FOXA1 is an important modulator of
UPK family member expression. However, it is important to note
that promoter regulation is achieved through the coordinated
binding of several transcription factors to cis regulatory binding
sites, and UPK promoters are no exception. For example, steroid
hormone binding proteins such as members of the PPAR family
have been shown to be important for UPK promoter regulation
[44]. Furthermore, the transcription factor IRF-1 was recently
shown to play an important part in the regulation of UPK
promoter activity [5]. This would explain why although FOXA1 is
expressed in a variety of tissues, including the liver and prostate,
specific UPK proteins are not. Moreover, although FOXA1 is
seemingly expressed throughout the various layers of the
urothelium, UPK family members are relatively restricted to the
most luminal superficial or ‘‘umbrella’’ cell layer. This is probably
true because umbrella cells express transcription factors (and other
important regulatory proteins) that normally cooperate with
FOXA1 to restrict and regulate UPK promoter activity specifically
in umbrella cells. It is unclear why both FOXA1 and UPK
proteins are absent in the majority of cell lines examined in this
study, while only a subset of human tumors exhibit absence of
both FOXA1 and AUM (UPK) expression (Fig. 1). However, our
observation that FOXA1 knockdown in RT4 cells resulted in
increased UPK expression (Fig. 2) may provide an explanation.
FOXA1 expression may act to maintain UPK family member
expression at a relative steady state, and diminished FOXA1
expression may trigger an as yet unidentified compensatory
mechanism in RT4 cells to elevate UPK family member
expression. Compensatory mechanisms may include an increase
in the expression of IRF-1, PPAR isoforms, retinoic acid receptor
family members, and/or other unidentified factors. We have
performed microarray analysis on our engineered RT4 lines, and
as this information is available to other investigators, it may help in
the identification of such factors. The possibility that FOXA1
knockdown triggers a compensatory mechanism, which acts to
increase UPK expression, is supported by the observation that
even though FOXA binding sites were identified in UK1B,
FOXA1 KD in immortalized urothelium resulted in increased
Figure 5. FOXA1 negative tumor cells are proliferative. Dual immunofluorescence of radical cystectomy patient samples depicting co-
localization of FOXA1 (green) and proliferation marker Ki67 (red). Left panel is normal adjacent tissue (NAT, top left) and matched tumor (bottom left)
from a patient with UCC, while right panels depict normal adjacent tissue (NAT, top right) and squamous cell carcinoma (bottom right). Note that
while NAT from UCC depicted in left panel expresses FOXA1 and is Ki67 negative, NAT from patient with SCC displays a subpopulation of FOXA1-
negative, Ki67-positive cells. Both tumors (bottom panel) show a subpopulation of cells exhibiting mutually exclusive expression of FOXA1 and Ki67.
doi:10.1371/journal.pone.0036669.g005
FOXA and Bladder Cancer
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e36669expression of UPK1B [5]. Alternatively, the net effect of FOXA1
expression may be to repress UPK levels, or this observation may
be more reflective of the limitations of the RT4 cell line. In
summary, the role of FOXA1 in the regulation of UPK proteins is
complex, and more effort should be invested in lines of
investigation directed at uncovering the primary determinants of
urothelial-specific gene expression, as increased understanding of
the mechanisms that regulate UPK expression can reveal
important insights into the mechanisms responsible for normal
bladder organogenesis and urothelial differentiation.
In addition to loss of FOXA1 expression in a subset of UCC,
FOXA1 was negative in KSM and ,80% of SCC. In the western
world, KSM and SCC of the urinary bladder most often occurs in
patients who suffer from chronic bladder inflammation, often
associated with long term use of catheters to facilitate bladder
emptying in the setting of chronic bladder outlet obstruction or in
patients with paraplegia or chronic urinary tract infections [31,45].
Interestingly, deficiency of vitamin A, the precursor of retinoic
acid, has also been shown to lead to KSM in a number of different
epithelial types [46,47,48]. Diet-induced vitamin A deficiency has
been shown to result in KSM within the urothelium, apparently
Figure 6. Alterations in FOXA1 expression in RT4 and T24 cells results in changes in E-cadherin expression and cell behavior. (A)
Generation of RT4-Scrambled and RT4-FOXA1 KD cells, as well as T24-pLPCX (empty vector) and T24-FOXA1 overexpressing cells: FOXA1 knockdown
in RT4 cells resulted in decreased E-cadherin expression (A) and significantly increased cell proliferation at day 4 (B). Overexpression of FOXA1 in T24
cells resulted in increased E-cadherin expression (A), and significantly decreased cell proliferation (C). While manipulation of FOXA1 had no impact on
in vitro invasion of RT4 cells (D), overexpression of FOXA1 in T24 cells significantly decreased cell invasion (D). RT4 cells stably expressing scrambled
construct (RT4-Scrambled) or FOXA1-specific shRNA (RT4-FOXA1 KD) were recombined with embryonic bladder mesenchyme (eBLM) isolated from
embryonic-16 day old rats and inserted under the kidney capsule of immunocompromised mice. After three weeks, host mice were injected with
BrdU and sacrificed. (E and F) Tumor volume was significantly increased in FOXA1-KD RT4 cells. (G) H&E (top panel) and BRDU staining (bottom panel)
of RT4-Scrambled and RT4-FOXA1 KD cells. H&E staining shows presence of fibromuscular stroma following recombination with both cell lines. RT4-
FOXA1 KD cells showed increased incorporation of BrdU (G), indicating FOXA1 knock down results in increased bladder cancer cell proliferation.
doi:10.1371/journal.pone.0036669.g006
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urethra and extending to trigone-associated urothelium and
restricted regions of the bladder dome [49]. The observation that
FOXA1 expression is induced by all trans-retinoic acid treatment
in ESC [4], as well as the demonstration that FOXA1 expression is
regulated by binding of the retinoic acid/vitamin A receptor to the
cis regulatory region of the FOXA1 gene [50] implicates down
regulation of FOXA1 during development of KSM. These
findings may also provide an explanation for the loss of FOXA1
observed in our analysis of KSM and SCC. The connection
between vitamin A, FOXA1 and squamous differentiation
requires further investigation.
Our observation that expression of FOXA1 and the prolifer-
ation marker Ki67 in human bladder cancer specimens is largely
mutually exclusive suggests alterations in FOXA1 expression
influence bladder cancer cell proliferation. This observation is
supported by the fact that silencing of FOXA1 in RT4 human
bladder cancer cells enhanced in vitro and in vivo RT4 proliferation
and significantly increased tumor volume. In further support of
this conclusion, overexpression of FOXA1 in T24 bladder cancer
cells significantly decreased in vitro proliferation. However, while
FOXA1 silencing resulted in increased in vivo tumor proliferation,
this did not appear to result in increased invasion in our tissue
recombination experiments. This is in contrast to our finding that
forced expression of FOXA1 decreased the in vitro invasiveness of
T24 cells. A major genetic difference between the established RT4
and T24 cell lines is the status of p 53 and PTEN expression.
While RT4 cells are wild-type for p 53 and PTEN, T24 cells are
p 53 null and PTEN mutant. The fact that FOXA1 knockdown
had little influence on RT4 invasiveness, while FOXA1 overex-
pression slowed T24 cell invasion in vitro may suggest that loss of
FOXA1 expression may cooperate with inactivation of p 53 and
or PTEN to promote aggressive behavior of bladder cancer cells.
While this needs further experimental verification, such a
suggestion is supported by the recent report that dual inactivation
of p 53 and PTEN was required to drive RT4 invasion in a tissue
recombination model [51]. In addition, microarray analysis
indicated FOXA1 overexpression in T24 cells increased expres-
sion of E-cadherin. These findings were verified by western
blotting analysis (Fig. 6). Recently, FOXA binding sites were
identified in the E-cadherin promoter, and diminished FOXA1
expression was shown to result in decreased E-cadherin expression
in poorly differentiated pancreatic ductal adenocarcinoma [32].
Loss of E-Cadherin expression has been repeatedly implicated in
the aggressive behavior of bladder cancer [52,53,54], and future
work is planned to investigate the link between FOXA1 and E-
cadherin in bladder cancer.
The tissue recombination xenografting system is unique because
it combines the strength of sub-cutaneous xenografting (relative
cost effectiveness) and orthotopic xenografting (provision of
stromal component) to foster increased understanding regarding
the influence of tissue microenvironment. This approach has been
used by other investigators to extensively study the role of stromal-
epithelial interactions in urogenital development [2,55,56], pros-
tate cancer [57,58], and more recently in bladder cancer studies
[51]. This is because an important defining strength of the tissue
recombination model is the ability to use genetically manipulated
eBLM derived from transgenic mice for tissue recombination,
which can influence bladder epithelial cell growth [59,60,61].
While the focus of the present research was on the role of FOXA1
in BLCa cells, tissue recombination xenografting enables the
incorporation of bladder mesenchyme associated determinants of
disease in future studies [62,63,64]. Moreover, future studies
exploring the cooperation between epithelial factors (such as
FOXA1 loss), and stromal contributors to disease pathogenesis can
be studied in this system. Therefore, as our understanding of the
role of the tumor microenvironment in bladder cancer evolves,
isolation of eBLM from transgenic mice, and the application of
approaches used in the study of prostate differentiation and tumor
progression through the isolation of transgenic urogenital mesen-
chyme [65,66] will allow the design of novel experiments
regarding BLCa tumor initiation and progression.
In conclusion, by showing alterations in FOXA family member
expression, this work serves as the foundation for future efforts to
elucidate the role of FOXA family members in the development of
MIBC. Our findings both support previous reports suggesting an
important role for FOXA family members in normal urothelial
differentiation and suggest that gene expression networks con-
trolled by FOXA family members may be implicated in the
malignant progression of urothelial neoplasms.
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